GLP-1 drug costs surge in Canada: what private insurance data reveals about access gaps

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Semaglutide (sold in Canada as Ozempic for type 2 diabetes, Rybelsus as an oral tablet, and Wegovy for chronic weight management) drove a 47.7% increase in GLP-1-related insurance costs in 2025, according to a report released September 29, 2026 by GreenShield, one of Canada's largest private health benefits administrators. The drug accounted for 6.6% of total drug insurance spending across GreenShield's book of business, and the average claimant spent $2,489 CAD on GLP-1 medications last year. For Canadians with private workplace benefits, that cost is at least partially absorbed. For those without, it largely is not.

The GreenShield data covers privately insured Canadians, which means it captures only one slice of the population. Millions of Canadians rely on provincial drug plans, and coverage for GLP-1 drugs varies sharply by province and by the specific indication on the prescription. A patient in Ontario using Ozempic for type 2 diabetes may qualify for Ontario Drug Benefit (ODB) coverage; a patient prescribed Wegovy for obesity management almost certainly will not, because most provincial formularies have not added weight-management GLP-1s. Health Canada has approved both Ozempic (2018) and Wegovy (2021) for their respective indications, but regulatory approval and provincial reimbursement are separate decisions made on separate timelines.

What this means in Canada

Health Canada's approval of semaglutide products does not obligate any province to cover them. As of September 2026, Ozempic is listed on most provincial formularies for type 2 diabetes with restrictions, but Wegovy's reimbursement status is far more limited. Quebec's RAMQ, British Columbia's PharmaCare, Ontario's ODB, and Alberta's AHCIP (Alberta Health Care Insurance Plan) have each taken different positions, and none has issued blanket coverage for obesity as a standalone indication.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specifically on GLP-1 access gaps, though the organization has flagged metabolic health as a concern in perimenopause and menopause care. The Canadian Medical Association Journal (CMAJ) published commentary in 2024 noting that obesity pharmacotherapy coverage in Canada lags behind clinical evidence, a gap the GreenShield data now quantifies in dollar terms.

Canada's national pharmacare framework, established under Bill C-64 in 2024, initially prioritized diabetes medications and contraceptives. GLP-1 drugs prescribed for diabetes are within scope, but the weight-management indication remains outside the first-phase formulary. The federal government has not announced a timeline for expanding coverage to obesity pharmacotherapy.

For patients using Canadian telehealth platforms such as Felix, Maple, or Science & Humans (scienceandhumans.com) to access GLP-1 prescriptions, the out-of-pocket cost question is immediate. These platforms can connect patients with licensed Canadian physicians who can prescribe semaglutide, but the prescription cost itself depends on whether the patient has private benefits and what their plan covers.

What changed in 2025

The scale of the GreenShield numbers is worth sitting with. Total diabetes medication costs in the $2,000 to $2,999 annual range increased 594% among GreenShield claimants in 2025, while the number of claimants in that cost band rose 374.3%. Ozempic remained the single most-claimed diabetes drug at 41% of all diabetes claims, though its share slipped slightly from 43.2% in 2024, possibly reflecting some patients moving to Wegovy or to newer entrants.

GreenShield's report also flagged the possibility that costs could moderate in 2026 as generic GLP-1 formulations enter the Canadian market. Health Canada has received submissions for generic semaglutide products, though no generic has received full approval as of this article's publication date. If generics do arrive, the price pressure on both private plans and provincial formularies could shift the reimbursement calculus.

The same GreenShield report documented a parallel surge in ADHD medication costs, with methylphenidate and lisdexamfetamine both rising sharply. Women aged 35 to 44 showed the fastest growth in ADHD claims, up 23.1% year over year, a pattern that aligns with growing clinical recognition that ADHD in adult women has historically been underdiagnosed. That demographic overlap with perimenopause, a life stage when hormonal shifts can amplify attention difficulties, is a question researchers are actively studying, though no Canadian clinical guideline has yet formalized the connection.

What Canadian patients should know

If you are currently taking or considering a GLP-1 drug in Canada, the first practical question is which indication your prescription carries. A prescription written for type 2 diabetes management has a different reimbursement path than one written for chronic weight management, even if the molecule is identical.

Patients with private group benefits should review their drug plan's formulary tier for semaglutide and check whether prior authorization is required. Many plans added GLP-1 coverage in 2024 and 2025 but with annual cost caps or step-therapy requirements (meaning a patient may need to try an older drug first).

Patients on provincial drug plans should contact their provincial drug benefit program directly. Eligibility criteria differ: some provinces require a confirmed type 2 diabetes diagnosis and a specific HbA1c threshold; others require specialist documentation. A family physician or endocrinologist can help navigate the prior authorization process.

Patients without either private benefits or provincial eligibility face the full list price, which for Wegovy runs approximately $350 to $450 CAD per month depending on dose and pharmacy. Novo Nordisk, the manufacturer, operates a patient support program in Canada called Ozempic Care and a separate program for Wegovy; eligibility criteria apply and these programs are not a substitute for systemic coverage.

Canadian telehealth services including Felix, Cleo, Maple, and Science & Humans can facilitate prescriptions and in some cases help patients navigate insurance paperwork, but none of these platforms controls what a provincial formulary will reimburse.

Limitations and open questions

The GreenShield report covers only privately insured Canadians, so it does not capture the experience of uninsured patients, those on social assistance drug programs, or seniors on provincial seniors' drug plans. The 47.7% cost increase figure reflects GreenShield's own claims book and may not be representative of the broader Canadian population.

Health Canada has not yet issued guidance on how generic semaglutide approvals will be sequenced or whether biosimilar pathways apply. The SOGC has not issued a position on GLP-1 access equity. CIHR (Canadian Institutes of Health Research) has funded some metabolic disease research but no large Canadian trial has yet reported on GLP-1 access disparities by province or income level.

The connection between ADHD diagnosis rates in women aged 35 to 44 and hormonal factors, including perimenopause, is biologically plausible and increasingly discussed in clinical literature, but Canadian clinical guidelines have not yet addressed it formally.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.